These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34181616)

  • 1. Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool.
    Kauke M; Haug V; Obed D; Diehm Y; Tchiloemba B; Safi AF; Pomahac B
    Plast Reconstr Surg; 2021 Jul; 148(1):194-202. PubMed ID: 34181616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Distribution of Potential Vascularized Composite Allotransplant Donors, Implications for Optimizing the Donor-recipient Match.
    Mendenhall SD; Ginnetti MT; Sawyer JD; Verhulst SJ; West BL; Levin LS; Neumeister MW
    Plast Reconstr Surg Glob Open; 2018 Jun; 6(6):e1833. PubMed ID: 30276058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C.
    Schlendorf KH; Zalawadiya S; Shah AS; Perri R; Wigger M; Brinkley DM; Danter MR; Menachem JN; Punnoose LR; Balsara K; Sacks SB; Ooi H; Awad JA; Sandhaus E; Schwartz C; O'Dell H; Carver AB; Edmonds CL; Ruzevich-Scholl S; Lindenfeld J
    JAMA Cardiol; 2020 Feb; 5(2):167-174. PubMed ID: 31851352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-recipient human leukocyte antigen matching practices in vascularized composite tissue allotransplantation: a survey of major transplantation centers.
    Ashvetiya T; Mundinger GS; Kukuruga D; Bojovic B; Christy MR; Dorafshar AH; Rodriguez ED
    Plast Reconstr Surg; 2014 Jul; 134(1):121-129. PubMed ID: 25028821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.
    Abdelqader A; Kabacam G; Woreta TA; Hamilton JP; Luu H; Al Khalloufi K; Saberi B; Philosophe B; Cameron AM; Gurakar A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):1-5. PubMed ID: 28260422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing increased risk for disease transmission (IRD) kidneys for pediatric renal transplant recipients.
    Hwang CS; Gattineni J; MacConmara M
    Pediatr Nephrol; 2019 Oct; 34(10):1743-1751. PubMed ID: 31243535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Use of Hearts From Hepatitis C Viremic Donors.
    Moayedi Y; Fan CPS; Gulamhusein AF; Manlhiot C; Ross HJ; Teuteberg JJ; Khush KK
    Circ Heart Fail; 2018 Dec; 11(12):e005276. PubMed ID: 30562093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?
    Saghafi H; Qorashi M; Heidari A
    Transplant Proc; 2009 Sep; 41(7):2761-3. PubMed ID: 19765428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human herpesvirus 6 in donor biopsies associated with the incidence of clinical cytomegalovirus disease and hepatitis C virus recurrence.
    Guardia AC; Stucchi RS; Sampaio AM; Milan A; Costa SC; Pavan CR; Boin Ide F
    Int J Infect Dis; 2012 Feb; 16(2):e124-9. PubMed ID: 22178541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients.
    Ting PS; Hamilton JP; Gurakar A; Urrunaga NH; Ma M; Glorioso J; King E; Toman LP; Wesson R; Garonzik-Wang J; Ottmann S; Philosophe B; Sulkowski M; Cameron AM; Durand CM; Chen PH
    Transpl Infect Dis; 2019 Dec; 21(6):e13194. PubMed ID: 31609520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients.
    Gasink LB; Blumberg EA; Localio AR; Desai SS; Israni AK; Lautenbach E
    JAMA; 2006 Oct; 296(15):1843-50. PubMed ID: 17047214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guiding Strategies for the Future of Vascularized Composite Allotransplantation: A Systematic Review of Organ Donation Campaigns.
    Mills E; Felsenheld JH; Berman ZP; Alfonso AR; Diep GK; Wolfe EM; Park JJ; Hoffman AF; Ramly EP; Rodriguez ED
    Plast Reconstr Surg; 2020 Oct; 146(4):922-934. PubMed ID: 32970015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.
    Sawinski D; Forde KA; Lo Re V; Goldberg DS; Cohen JB; Locke JE; Bloom RD; Brensinger C; Weldon J; Shults J; Reese PP
    Am J Kidney Dis; 2019 Jun; 73(6):815-826. PubMed ID: 30704882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast patterns of Cytomegalovirus and Epstein-Barr virus infection in pediatric living-donor liver transplant recipients.
    Nafady-Hego H; Elgendy H; Uemoto S
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():75-82. PubMed ID: 25894132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience.
    Ofosu A; Durand CM; Saberi B; Alqahtani S; Ucbilek E; Belden M; Cameron AM; Gurakar A
    Exp Clin Transplant; 2015 Nov; 13 Suppl 3():7-10. PubMed ID: 26640901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B and C serologic profiles of Canadian organ donors and recipients: retrospective 10-year review at a single center.
    Burton CE; Doucette KE; Mabilangan CA; Plitt SS; Lee BE; Preiksaitis JK
    Transpl Infect Dis; 2016 Aug; 18(4):520-8. PubMed ID: 27226204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric vascularized composite allotransplantation: What is the landscape for obtaining appropriate donors in the United States?
    Mendenhall SD; Sawyer JD; West BL; Neumeister MW; Shaked A; Levin LS
    Pediatr Transplant; 2019 Aug; 23(5):e13466. PubMed ID: 31081211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.
    Cypel M; Feld JJ; Galasso M; Pinto Ribeiro RV; Marks N; Kuczynski M; Kumar D; Bahinskaya I; Bagnato VS; Kurachi C; Slutsky AS; Yeung JC; Donahoe L; de Perrot M; Yasufuku K; Pierre A; Binnie M; Chaparro C; Martinu T; Chen M; Tikkanen J; Chow CW; Sidhu A; Waddell TK; Keshavjee S; Singer LG; Humar A
    Lancet Respir Med; 2020 Feb; 8(2):192-201. PubMed ID: 31606437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Hepatitis C Virus Antibody-Positive Donor Livers in Hepatitis C Nonviremic Liver Transplant Recipients.
    Luckett K; Kaiser TE; Bari K; Safdar K; Schoech MR; Apewokin S; Diwan TS; Cuffy MC; Anwar N; Shah SA
    J Am Coll Surg; 2019 Apr; 228(4):560-567. PubMed ID: 30586641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study.
    Franco A; Moreso F; Merino E; Sancho A; Kanter J; Gimeno A; Balibrea N; Rodriguez M; Perez Contreras F
    Transpl Int; 2019 Jul; 32(7):710-716. PubMed ID: 30773693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.